Discussion
Canada’s Drug Agency (CDA) recommends expanding public funding for Biogen’s Spinraza (nusinersen) to include adults and more patients with spinal muscular atrophy (SMA). Provincial governments have yet to decide on funding. Still in draft form, the recommendation is to include adults with SMA type 2 or…